Item 2.02 Results of Operations and Financial Condition. On May 12, 2026, NeuroOne Medical Technologies Corporation (the “ Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “ Current Report”) and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 12, 2026 ─────────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded with Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: May 12, 2026 By: /s/ David Rosa David Rosa Chief Executive Officer